70 likes | 163 Views
SoGAT XVI, Langen 3 rd July 2003. Immediate Parvo B19 NAT testing of pooled donor samples: logistics and problems. W. Kurt Roth Red Cross Blood Transfusion Service Baden-Württemberg – Hessen, Institute Frankfurt am Main. B19 / HAV-PCR: Testing Strategy.
E N D
SoGAT XVI, Langen 3rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and problems W. Kurt Roth Red Cross Blood Transfusion Service Baden-Württemberg – Hessen, Institute Frankfurt am Main
B19 / HAV-PCR: Testing Strategy • B19 and HAV PCR in parallel to HCV, HIV and HBV PCR • Aliquots of same extract as for HCV, HIV, HBV • Relevant for all blood components incl. platelets • Quantitative TaqMan PCR with internal control sequence • 95% detection limit: 103 IU / ml (B19 and HAV) • B19 positive Pools 105 IU / ml: • Positive donation identified • Positive donation destroyed • B19 positive Pools < 105IU / ml: • Positive donation not identified • All donations released (weak positive)
Pool Deconstruction HCV, HBV, HIV, HAV, B19 PCR-only positives PCR and antibody positives 8 x 12 1 x 94 12 x 8 individual testing
HAV / Parvo B19-PCR: Results April 2000 – May 2003: Sensitivity 105 IU / ml Rate of B19 positives at a sensitivity of 103 IU/ ml: 1 : 700
Parvo B19 Positives per Month Total Positives 105 (n) Frankf West
Indications for B19-negative components • Parvo B19-negative (< 103 IU / ml) components upon specific written request; individual label: „Parvovirus B19 not detectable“ • Patients with BMT, SCT • B19 antibody-negative pregant women in the 1.and 2. trimenon • HIV patients • Additional risk groups e.g. • transient aplastic crisis • pure red cell aplasia • Parvo B19-negative and weak positive (> 103 ; < 105 IU / ml) components for all patients at no specific risk (no label); standard quality
Parvo-B19 Seroconversion Medac IgM and IgG ELISA; Mikrogen IgG/IgM recomBlot